Skip to main content
Jennison Associates logoJennison Associates logo
  • About Us
  • Equity

    • Large Cap Growth
    • Global
    • International
    • Emerging Markets
    • Mid Cap Growth
    • Small Cap Core

    Equity

    • SMid Cap Core
    • Large Cap Value
    • Global Equity Income
    • Rising Dividend

    Thematic Equity

    • Health Sciences
    • Utility Equity
    • Global Infrastructure
    • Global Natural Resources
    • MLP (Master Limited Partnerships)
    • Financial Services

    Thematic Equity

    • Technology Equity
  • Fixed Income
    • Active Long Duration
    • Active Core
    • Active Intermediate
    • Stable Value
    • LDI
  • ESG Overview
    • Integration
    • Proxy Voting
    • Engagement
    • Corporate Citizenship
  • Perspectives
  • Contact Us
Image: virus, bacteria vector background.
Coronavirus

Living in the Age of COVID-19 Part IILivingintheAgeofCOVID-19PartII

Sep 29, 2020

10 mins

Learn More

Jennison Associates health sciences equity portfolio manager and research analyst Debra Netschert recently spoke with Dr. Larry Brilliant, a world-renowned epidemiologist, about the latest information on COVID-19. Click on the arrow below to watch the video of their discussion. Download a detailed textual summary by clicking the Learn More button on the right. 

Main Points

  • It could be 4-6 years before COVID-19 is controlled globally. That doesn’t mean that life as we’ve known it will be upended that long but that we’ll be fighting COVID-19 somewhere in the world for many years to come.
  • By year-end, we could have a handful of vaccines that have gone through a clinical trial and have met the US Food and Drug Administration’s (FDA) low bar for efficacy – 50% -- and have begun to be tested against the higher bar for safety.
  • We might have a vaccine within a year of detecting COVID-19. Development of therapeutic antibodies and antivirals has also been promising. The goal of a $5, 5-minute test with 99% sensitivity and specificity is not far away.
  • Schools can be made safe, but it’s complicated, and there’s no room to cut corners. The first rule of safety is testing. Air filters should be changed often, Plexiglas barriers should be erected, and social distancing should be practiced at all times.
  • Data is sparse, but children under the age of 10 have more virus in their nasopharynx, or upper throat, than adults. Children can presumably spread the virus. Most children will be asymptomatic, and a plurality will have mild symptoms, but for some the effects will be much more serious. Of children who are hospitalized, a high percentage – roughly a third -- end up in intensive care units. We don’t know pre-existing determinants that might predict the severity of the disease in children.
  • In some instances, it’s possible to return to work. But if your work site has low ceilings, poor ventilation, limitations on social-distancing, and other challenges, it’s not a great idea. A safe return to the office, like a safe return to school, requires careful planning.
  • Like smallpox, COVID-19 has systemic effects. Almost all symptomatic patients have acute then chronic pneumonia and difficulty breathing. About a third have enduring myocardial disease. Many develop kidney disease, others leaky capillary syndrome. It can cause swelling of the toes, and many lose their sense of smell. Many surviving patients are sick for months, and we don’t yet know what the lasting effects will be.
  • The disease can be spread by someone who has not yet shown symptoms. The period of maximal communicability is four days before and four days after symptoms first appear. Eight or nine days after symptoms manifest, the virus transforms from a nasopharynx phenomenon to a systemic disease where autoimmune complications arise, and perhaps surprisingly, the virus becomes less contagious.
  • Everyone should get a flu vaccine now. First, you want to reduce the possibility of contracting both the flu and COVID-19 at the same time. Second, mass flu inoculation should lower the risk of misdiagnoses – COVID-19 and the flu share early-stage symptoms, so someone infected with COVID-19 could be diagnosed as having the flu and vice versa.
  • Rushing a vaccine for political purposes is dangerous and would likely undermine trust in health institutions. There is no possibility that we will know over the next couple of months that a vaccine is safe – it’s logistically impossible given the time it takes to assess reactions of many different segments of the population.
  • To develop herd immunity from COVID-19 without a vaccine, 220 million Americans would have to contract the disease with the risk of millions becoming very sick or dying.
Learn More
Contact Us
Jennison Associates

Jennison's investing approach is rooted in our fundamental research and security selection; all of our portfolios are built from the bottom-up, security by security.

Contact Us

The information in this material has been obtained from sources that Jennison believes to be reliable as of the date presented; however, Jennison cannot guarantee the accuracy of such information, assure its completeness, or warrant such information will not be changed. The information contained herein is current as of the date of issuance (or such earlier date as referenced herein) and is subject to change without notice. Jennison has no obligation to update any or all such information; nor do we make any express or implied warranties or representations as to the completeness or accuracy. Any reproduction of this material, in whole or in part, or the disclosure or redistribution of any of its contents, without the prior written consent of Jennison, is prohibited.

Any projections or forecasts presented herein are subject to change without notice. Actual data will vary and may not be reflected here. No liability whatsoever is accepted for any loss (whether direct, indirect, or consequential) that may arise from any use of the information contained in or derived from this material. Jennison may make investment decisions that are inconsistent with the recommendations or views expressed herein.

  • About Us

    • About Jennison
    • Firm Profile
    • Our Approach to Investing
    • Contact Us - Form
  • Other Resources

    • Form CRS
Jennison Associates logo
  • Terms & Conditions
  • PGIM Privacy Center
  • Accessibility Help
  • Cookie Preference Center

Jennison Associates LLC. All Rights Reserved.

This website is intended for Institutional and Professional Investors only. All investments involve risk, including the possible loss of capital.

Important Disclosures

Jennison Associates is a registered investment advisor and a Prudential Financial company. Jennison Associates LLC has not been licensed or registered to provide investment services in any jurisdiction outside the United States. Certain investment vehicles are distributed or offered through Prudential Investment Management Services LLC (also a Prudential Financial Company) or other affiliated entities. Additionally, vehicles may not be registered or available for investment in all jurisdictions.

Please click on this disclosure link for important information, including information on non-US jurisdictions.

This web site is not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services. It does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. This is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence.

Any views or opinions expressed on this website reflect the opinions of Jennison investment professionals at the time they are made and are subject to change.

Your investment objectives, risk tolerance, and liquidity needs must be reviewed before suitable programs can be recommended. Asset allocation and diversification strategies do not assure a profit or protect against loss in declining markets. Investors should consult with their attorney, accountant, and/or tax professional for advice concerning their particular situation.

Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that the investment managers’ objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors.

There is no guarantee our objectives will be met. All investments contain risk, including possible loss of principal. The strategy may vary significantly from the benchmark in several ways including, but not limited to, sector and issuer weightings, portfolio characteristics, and security types.

Information for persons in the United Kingdom and various European Economic Area jurisdictions
In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA  Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. Jennison Associates LLC, PGIM Limited & PGIM Netherlands B.V. are wholly owned subsidiaries of PGIM, Inc. the principal investment management business of Prudential Financial, Inc. (‘PFI’).  PFI of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined  under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II).

Links to third-party sites are intended for informational purposes only and should not be considered investment advice or recommendation to invest. These links do not constitute endorsement or confirm their accuracy, and we are not responsible for any third-party guidelines, security, or accuracy of information.

You are viewing this page in preview mode.

Edit Page